Saturday 17 October 2026
Export RZLT’s income statement to Excel — free account
Rezolute, Inc.
RZLT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 23.1% and free cash flow grew 40.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.58
0.32
−8.21%
Follow RZLT
Rezolute, Inc. (RZLT) P/E ratio
Rezolute, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| FENC Adherex Technologies Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| EDIT Editas Medicine, Inc. compare | n/m |
| SPRY ARS Pharmaceuticals, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | n/m |
| RZLT Rezolute, Inc. | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ZURA Zura Bio Limited compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)